Avalo Therapeutics (NASDAQ:AVTX) Releases Quarterly Earnings Results, Misses Expectations By $0.25 EPS

Avalo Therapeutics (NASDAQ:AVTX) announced its quarterly earnings results on Thursday. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25), FiscalAI reports.

Avalo Therapeutics Trading Down 2.0%

NASDAQ AVTX opened at $18.32 on Friday. The firm’s fifty day simple moving average is $17.26 and its two-hundred day simple moving average is $16.29. The firm has a market capitalization of $969.13 million, a P/E ratio of -4.19 and a beta of 0.80. Avalo Therapeutics has a 12-month low of $8.29 and a 12-month high of $24.27.

Insider Buying and Selling at Avalo Therapeutics

In related news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider directly owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is owned by insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics in the 3rd quarter worth approximately $143,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth approximately $56,000. Jump Financial LLC purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Avalo Therapeutics during the 4th quarter valued at approximately $274,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AVTX shares. Citizens Jmp reduced their price objective on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Bank of America began coverage on Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Finally, HC Wainwright decreased their price objective on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.10.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.